Noble financing effort

James Noble resigned as British Biotech's finance director, declaring that the company is "fully funded through to commercialization." BBIOY raised, by Ebb & Flow's count, about $500 million during Noble's watch, most notably the company's June 1996 rights offering that raised £143.4 million (US$234 million), on top of £47.5 million ($71.2 million) garnered from a warrant exercise in January 1996. Before joining BBIOY in 1990, he was involved with BBIOY's 1989 £22.7 million (about $34 million) fundraising as a member

Read the full 800 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE